GlassScriptPhysician profile
Donna Delaine Eoff
NPI 1073017463
$4,644.50
in general payments reported to CMS, 2019-2025
24 companies · $18.47 in 2025
The $18.47 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $2,233 · 2023: $1,770 · 2024: $479 · 2025: $18.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954 · Travel and Lodging: $281 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.44 |
| Travel and Lodging | $281.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,756.98 | 2022-2023 | Interstim |
| Axonics, INC. | $948.19 | 2022-2024 | Axonics |
| Sumitomo Pharma America, INC. | $369.35 | 2023-2024 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $348.43 | 2021-2024 | Veozah |
| Myriad Genetic Laboratories, INC. | $234.86 | 2023 | Prolaris |
| Novo Nordisk INC | $212.13 | 2024 | Wegovy |
| Abbvie INC. | $129.81 | 2022-2024 | |
| Endo Pharmaceuticals INC. | $115.11 | 2022-2023 | Xiaflex, Aveed, Edex |
| Urovant Sciences INC | $100.25 | 2022 | |
| Urogen Pharma, INC. | $67.34 | 2022-2023 | Jelmyto |
| Bluewind Medical | $59.83 | 2024 | Revi |
| Myovant Sciences INC. | $39.72 | 2022 | |
| Rochester Medical Corporation | $32.54 | 2022 | |
| Verity Pharmaceuticals INC. | $29.54 | 2023-2024 | Trelstar |
| Boston Scientific Corporation | $29.03 | 2023 | Lithovue |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $28.73 | 2022 | |
| Tolmar, INC. | $24.72 | 2023 | |
| Progenics Pharmaceuticals, INC. | $19.20 | 2022 | |
| Galderma Laboratories, L.P. | $18.47 | 2025 | |
| Pfizer INC. | $18.32 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.84 | 2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $15.13 | 2023 | |
| Ferring Pharmaceuticals INC. | $15.08 | 2024 | Adstiladrin |
| Janssen Biotech, INC. | $14.90 | 2023 | Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Eoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.